




RealRate

PHARMACEUTICAL 2023

Xeris Biopharma Holdings Inc. Rank 305 of 446





RealRate

PHARMACEUTICAL 2023

Xeris Biopharma Holdings Inc. Rank 305 of 446



The relative strengths and weaknesses of Xeris Biopharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Xeris Biopharma Holdings Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -5.3%, being 48% points below the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 186,818 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 143,466 |
| Liabilities, Current | 73,621 |
| Liabilities, Non-Current | 9,433 |
| Other Assets | 8,722 |
| Other Compr. Net Income | 8.0 |
| Other Expenses | 32,053 |
| Other Liabilities | 216,281 |
| Other Net Income | -14,144 |
| Other Revenues | 110,248 |
| Property and Equipment | 5,516 |
| Research and Development | 20,966 |
| Selling, General and Administrative Expense | 137,745 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 344,522 |
| Liabilities | 299,335 |
| Expenses | 190,764 |
| Revenues | 110,248 |
| Stockholders Equity | 45,187 |
| Net Income | -94,660 |
| Comprehensive Net Income | -94,656 |
| Economic Capital Ratio | -5.3% |